Member Info for cottoner

Most of those 50k batches have been buys IMO.

They have exactly matched the buying price at the time.

On occasions today the selling price has been higher than the buying price.

Sorry - had another look at what you said.

Silly question!

They will be out soon and I'd prefer to be in when that moment occurs.

How will you know?

This for a start:
Europe's only 24 bedroom quarantine clinic with onsite virology lab in Queen Mary's Hospital London

Today's Shares magazine contains a 3 page Shares Spotlight article on ORPH, entitled

Open Orphan lining up for role in coronavirus fight.

100/1 shot they pull off a deal. !

After announcing this some time ago:

It confirms that the Company is in discussion with multiple potential licensees in Japan and Asia, including but not limited to its NXP002 programme.

I'd hope the odds of a deal are a lot better than that. :-)

Including the exercise of the warrants detailed above, the Company has received subscriptions totalling €2.9m since 31 January 2020. The Company also confirms that, following the exercise of the warrants above, there are no outstanding warrants or options over Ordinary Shares in issue.

Afraid if there's material news to be released it has to be released - you can't release it when it suits you.

He's written a book called Biotechnology Valuation.

https://www.amazon.com/Biotechnology-Valuation-Introductory-Karl-Keegan/dp/0470511788

CF stated recently that it would be pointless doing presentation after presentation if there was no new information to present.

ORPH are presenting at 2 events on Feb 25th , a ShareSoc Growth Company Seminar in Manchester and a Shares Magazine Investor Event in London.

As they are on the same night ,one will be presented by CF and the other by Trevor Phillips, CEO.

On that basis, I'd expect some new material news to be released before/on Feb 25th so that information can be included in those forthcoming presentations.

Additionally ORPH have already earmarked further presentations for March 11th , March 17th and March 26th , so on the same basis I'd also expect further news to be released in relatively quick time.

Didn't want to reignite arguments with my initial post.

Was done with a :-)

Full Times snippet.

Eastern promise for Nuformix
Shares in Nuformix, the Cambridge-based drug company, gave up recent gains yesterday to trade 5 per cent lower and close at 8¼p.

Chatter that Nuformix is close to securing a licensing deal with Kissei Pharmaceutical, one of Japan’s largest drug companies, has sent shares in the minnow higher in recent days.

Nuformix uses co-crystal technology to re-engineer drugs. Market gossip suggests that Kissei is in talks to license Nuformix’s lead fibrosis treatment alongside its unique oral delivery system.

The proprietary delivery mechanism resolves a number of efficacy problems that have plagued Kissei for years, they claim. The partnership could enable Kissei to treat other conditions.

The reports suggest that the deal being discussed involves an upfront milestone payment of £15 million and annual royalty payments worth more than £200 million.

If a deal is struck and structured on those terms, Nuformix would generate revenues well in excess of its current £40 million market value.

Established in 2008, Nuformix set out to identify known drug molecules with the potential to function as innovative therapies for unmet medical needs.

In addition, certain Bondholders have elected to convert a total of 67,687 Bonds into new ordinary shares of 1p each in the capital of the Company ( the "Ordinary Shares") at a price of 1p per share, pursuant to the terms of the Convertible Bond. Accordingly, 6,768,700 new Ordinary Shares will be issued to the Bondholder in accordance with the terms of the Convertible Bond (the "Conversion Shares").

i.e £67.687K @ 1p , almost double the current price.

wrt NXP002

Reports Results from Novel IPF Pre-Clinical Trial
RNS Number : 1394J
Nuformix PLC
03 December 2018

NXP002 out-performed current standard of care treatment, Esbriet ® (pirfenidone)

For info:

FDA approved Esbriet for treatment of idiopathic pulmonary fibrosis in 2014. The drug, whose revenue stood at $48 million in 2014, garnered nearly $856 million in 2017

For all the negativity at the moment , I've still to see any negative news , scientifically speaking regarding any of their lead programmes.

Along as this remains the case I remain hopeful.

I'll take that as a positive.

'Management expects a material contribution on revenue from this partnership this year.'

Time you had a look at a calendar then. :-)

My only surprise this morning is that it took you so long to post that.

Looks like he Often disappears!